A Study of MGC026 in Participants With Advanced Solid Tumors

A Study of MGC026 in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer
Interventions: Biological: MGC026 Dose Escalation; Biological: MGC026 Dose for Expansion
Sponsors: MacroGenics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 16, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments